antibody inhibiting osteoclast differentiation,
activation, and survival with applicable suppression of bone turnover in patients with multiple
myeloma, osteolytic bone disease, and bone metastases from breast and prostatecancer.
It is also a useful drug for managing the GCT of bone and one excellent option in metastatic GCT.
The long time safety and complications, especially in young female patients, are to be proven.
Conclusions. Early diagnosis and accurate management of GCT are mandatory in order to achieve
good long-term clinical results. Denosumab treatment
. Ibrahim T, Flamini E, Fabbri L, Serra P, Mercatali L, Ricci R, Sacanna E, Falasconi MC, Casadei R, Galassi R et al. Multidisciplinary approach to the treatment of bone metastases: Osteo-oncology center, a new organizational model. Tumori. 2009; 95:291–297. 6. Bandini M, Pompe RS, Marchioni M, Zaffuto E, Gandaglia G, Fossati N, Cindolo L, Montorsi F, Briganti A, Saad F et al. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostatecancer patients: A population-based study. Int. Urol. Nephrol. 2018; 50:71–78. 7. Plunkett TA